These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38247049)

  • 1. Reply: Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
    Bradley CL; McMillin SM; Hwang AY; Sherrill CH
    Ann Pharmacother; 2024 Apr; 58(4):446-447. PubMed ID: 38247049
    [No Abstract]   [Full Text] [Related]  

  • 2. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
    Bradley CL; McMillin SM; Hwang AY; Sherrill CH
    Ann Pharmacother; 2023 Jul; 57(7):822-836. PubMed ID: 36367094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
    Jacob S; Varughese GI
    Ann Pharmacother; 2024 Apr; 58(4):444-445. PubMed ID: 38247052
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.
    Kadowaki T; Chin R; Ozeki A; Imaoka T; Ogawa Y
    Lancet Diabetes Endocrinol; 2022 Sep; 10(9):634-644. PubMed ID: 35914542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis.
    Karrar HR; Nouh MI; Nouh YI; Nouh MI; Khan Alhindi AS; Hemeq YH; Aljameeli AM; Aljuaid JA; Alzahrani SJ; Alsatami AA; Alkredees MA; Almuqati AO; Abanmi SN; Alshehri AM
    Cureus; 2023 Sep; 15(9):e46091. PubMed ID: 37908927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist.
    Tall Bull S; Nuffer W; Trujillo JM
    J Diabetes Complications; 2022 Dec; 36(12):108332. PubMed ID: 36375235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
    Urva S; Levine JA; Schneck K; Tang CC
    Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
    Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Gastaldelli A; Cusi K; Fernández Landó L; Bray R; Brouwers B; Rodríguez Á
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):393-406. PubMed ID: 35468325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
    Zeng Q; Xu J; Mu X; Shi Y; Fan H; Li S
    Front Endocrinol (Lausanne); 2023; 14():1214334. PubMed ID: 37908750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tirzepatide: A Systematic Update.
    Forzano I; Varzideh F; Avvisato R; Jankauskas SS; Mone P; Santulli G
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.
    Inagaki N; Takeuchi M; Oura T; Imaoka T; Seino Y
    Lancet Diabetes Endocrinol; 2022 Sep; 10(9):623-633. PubMed ID: 35914543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.
    Patel H; Khunti K; Rodbard HW; Bajaj HS; Bray R; Kindracki Z; Rodríguez Á
    Diabetes Obes Metab; 2024 Feb; 26(2):473-481. PubMed ID: 37853960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception.
    Skelley JW; Swearengin K; York AL; Glover LH
    J Am Pharm Assoc (2003); 2024; 64(1):204-211.e4. PubMed ID: 37940101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
    Boye KS; Thieu VT; Sapin H; Lee CJ; Landó LF; Brown K; Bray R; Wiese RJ; Patel H; Rodríguez Á; Yu M
    Diabetes Ther; 2023 Nov; 14(11):1833-1852. PubMed ID: 37526908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Battelino T; Bergenstal RM; Rodríguez A; Fernández Landó L; Bray R; Tong Z; Brown K
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):407-417. PubMed ID: 35468321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
    Heerspink HJL; Sattar N; Pavo I; Haupt A; Duffin KL; Yang Z; Wiese RJ; Tuttle KR; Cherney DZI
    Lancet Diabetes Endocrinol; 2022 Nov; 10(11):774-785. PubMed ID: 36152639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program.
    Frías JP
    Expert Rev Endocrinol Metab; 2023 Mar; 18(2):111-130. PubMed ID: 36908082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.
    Lingvay I; Mosenzon O; Brown K; Cui X; O'Neill C; Fernández Landó L; Patel H
    Cardiovasc Diabetol; 2023 Mar; 22(1):66. PubMed ID: 36964557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Efficacy and Safety of Tirzepatide in Asians and Non-Asians with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Cui Y; Yao J; Qiu X; Guo C; Kong D; Dong J; Liao L
    Diabetes Ther; 2024 Apr; 15(4):781-799. PubMed ID: 38402331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.